Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Yantai Lannacheng Biotechnology

Request full access

A company working with drug synthesis, radioactive labeling, preclinical cell and animal experiments, and molecular imaging

ChinaFounded 2021Biotech & Life Sciences

About Yantai Lannacheng Biotechnology

Yantai Lannacheng Biotechnology Co., Ltd. (LNC) is a clinical-stage biopharmaceutical company established in 2021 as a joint venture between Yantai Dongcheng Pharmaceutical Group, a prominent Chinese nuclear medicine enterprise, and Professor Xiaoyuan (Shawn) Chen, an expert in molecular imaging and nanomedicine. The company focuses on the development and registration of first-in-class, integrated radiotheranostics for oncological applications.

LNC's business strategy centers on creating its own pipeline of proprietary drug assets and then out-licensing them to larger biopharmaceutical partners who manage late-stage trials and commercialization. The company has successfully raised significant capital to fund its research and development, including a Series B+ financing round of 300 million RMB in April 2024, led by Shenzhen Capital Group. This followed earlier Series A and B funding rounds in 2022 and 2023, respectively.

The company's core technology revolves around a proprietary "albumin binder-Evans blue modification" platform, which enhances the tumor retention and absorbed dose of radiopharmaceuticals, allowing for potentially reduced dosages and less frequent administration. LNC's product pipeline is built upon this platform and includes radioligands based on small molecules, peptides, and antibodies. These products target a variety of solid tumors, such as prostate cancer, gastric cancer, gliomas, and neuroendocrine tumors, by targeting proteins like Fibroblast Activation Protein (FAP) and Prostate-Specific Membrane Antigen (PSMA). Several of its candidates have received Investigational New Drug (IND) approvals from regulatory bodies in the US, Singapore, and China and are advancing through clinical trials.

To support its R&D, LNC invested over 100 million RMB to build a 6,500-square-meter comprehensive laboratory in Yantai's "MediPark," which became operational in 2023. This facility integrates drug synthesis, radiolabeling, preclinical studies, and molecular imaging, forming the company's core translational medicine platform. Headquartered in Yantai, the company also operates a subsidiary in Singapore, LNC Pharma Pte. Ltd., to manage international affairs.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
54.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing Jul 2025 $41M $550M China Cinda Asset Management · Yantai Dongcheng Pharmaceutical · Shandong New Growth Drivers Fund ↗
SERIES BOther financing Apr 2024 $41M $309M Aowa Clean Energy · Shenzhen Capital Group · Qianhai FOF · Yantai Finance Development Investment Group ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Yantai Lannacheng Biotechnology website traffic

Latest recorded traffic for Yantai Lannacheng Biotechnology is 400 monthly website visits, up 900% over the last three months.

Latest monthly visits400 3-month web change+900%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Yantai Lannacheng Biotechnology in its local ecosystem

Live from Dealroom

The Yantai Lannacheng Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • Aowa Clean Energy
  • Shenzhen Capital Group
  • Qianhai FOF
  • Yantai Finance Development Investment Group
  • Longxin Investment

Series B and later3 investors entered at this stage

  • China Cinda Asset Management
  • Yantai Dongcheng Pharmaceutical
  • Shandong New Growth Drivers Fund
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Yantai Lannacheng Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Yantai Lannacheng Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.